Interestingly, these drugs, did not affect NF-κB activity in cells such as macrophages, but compromised the viability of human and murine melanoma cells by promoting apoptosis and inhibiting survival pathways and cell migration when used in the 0.5–1 μM range. Here, NFKB1 is linked to melanoma.